Biotech Showcase™ 2016: Interview: Roche doubles down on immuno-oncology trial collaborations

March 8, 2016
Roche partnering exec Jason Coloma explains his company’s approach to developing the next wave of immuno-oncology therapies, through collaborations. In the fast-paced, high value world of immuno-oncology development, the number of potential combinations of therapies, including doublet and triplet regimens, is enormous. Recognizing that means you won’t have everything in-house and will need to establish external collaborations with a wide range companies, Roche exec Jason Coloma explains to “The Pink Sheet” Senior Writer Emily Hayes. In 2015, Roche set up a cancer immunotherapy committee to evaluate the many proposals for novel combinations, says Coloma, head of oncology and cancer immunotherapy partnering at Roche. The efforts translated into a variety of collaborations last year, with more on the way for 2016. There is a vast array of potential targets and it’s still unclear which therapies will make the best partners for PD-1/L1 checkpoint inhibitors, which are at the forefront of development. It’s safe to say the jury is still out as the data is being generated for particular indications, Coloma explains. Find more videos and articles at http://www.partnering360.com/insight For more information on Biotech Showcase™, visit our webpage: http://www.ebdgroup.com/bts/index.php
Previous Video
Maximizing Your Success and Networking Objectives at the BIO-Europe Spring® Conference in Stockholm
Maximizing Your Success and Networking Objectives at the BIO-Europe Spring® Conference in Stockholm

On April 4–6, approximately 2,000+ executives and investors from the biotechnology and pharmaceutical indus...

Next Video
Biotech Showcase™ 2016: Interview: Probiodrug pursues modified abeta approach to tackle Alzheimer's
Biotech Showcase™ 2016: Interview: Probiodrug pursues modified abeta approach to tackle Alzheimer's

Probiodrug AG CEO Dr. Konrad Glund tells Mike Ward, global director of content for Informa's pharma insight...